康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

未开盘 06-16 16:08:14

84.650

-4.700

-5.26%

最高90.000	最低83.000	成交量1,658万
今开89.350	昨收89.350	日振幅7.83%
总市值779.63亿	流通市值779.63亿	总股本9.21亿
成交额14.01亿	换手率1.80%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":84.65,"timestamp":1781597294009,"preClose":89.35,"halted":0,"volume":16577974,"delay":0,"changeRate":-0.05260212646894224,"floatShares":921000000,"shares":921000000,"eps":-1.232771,"marketStatus":"未开盘","change":-4.7,"latestTime":"06-16 16:08:14","open":89.35,"high":90,"low":83,"amount":1401004194,"amplitude":0.078344,"askPrice":84.65,"askSize":7000,"bidPrice":84.6,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-1.37184,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781659800000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":89.35,"openAndCloseTimeList":[[1781573400000,1781582400000],[1781586000000,1781596800000]],"volumeRatio":0.854994,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":3.1892,"impliedVolPercentile":0.9899},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"1131801510","title":"异动解读｜康方生物盘中下跌3.41%，回购短暂提振后ASCO利好兑现抛压再度主导","url":"https://stock-news.laohu8.com/highlight/detail?id=1131801510","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131801510?lang=zh_cn&edition=full","pubTime":"2026-06-16 09:38","pubTimestamp":1781573890,"startTime":"0","endTime":"0","summary":"6月16日，康方生物盘中下跌3.41%，报86.2港元，成交额8954.66万港元。消息面上，公司核心产品依沃西HARMONi-6研究OS阳性结果于6月1日ASCO全体会议公布后，事件驱动型资金持续获利了结，股价较数据公布后高点累计跌幅已逾30%。此前公司董事会批准最多2亿港元回购计划及管理层拟增持合计不超过5000万港元曾短暂提振股价，但抛压再度主导走势。叠加美方可能限制对中国生物技术投资的传闻扰动及市场对创新药盈利能力的担忧，生物科技板块整体承压。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110086674","title":"康方生物新一代HER3 ADC药物AK138d1联合依沃西单抗：首例患者入组Ib/II期乳腺癌研究，推进\"IO2.0 + ADC2.0\"战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1110086674","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110086674?lang=zh_cn&edition=full","pubTime":"2026-06-15 14:53","pubTimestamp":1781506404,"startTime":"0","endTime":"0","summary":"康方生物的新一代HER3靶向抗体偶联药物AK138d1，与依沃西单抗联合疗法的Ib/II期乳腺癌临床研究，已迎来首例患者入组。这一进展标志着公司\"免疫治疗2.0（IO2.0）与抗体偶联药物2.0（ADC2.0）\"双平台协同发展战略的实质性推进。该研究旨在评估这一创新联合疗法在HER3表达阳性晚期实体瘤，特别是乳腺癌患者中的安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU0348784397.USD","LU2488822045.USD","LU0348735423.USD","LU2476274308.USD","LU0348827113.USD","LU0348825331.USD","LU1720050803.USD","LU0417516738.SGD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0348783233.USD","LU1794554557.SGD","LU0561508036.HKD","LU0417516571.SGD","IE00B543WZ88.USD","LU0634319403.HKD","LU0348767384.USD","BK1161","BK1574","LU0540923850.HKD","LU2476274720.SGD","LU1961090484.USD","LU0348766576.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150632681","title":"异动解读｜康方生物盘中下跌3.04%，回购计划短暂提振后ASCO利好兑现抛压再度主导","url":"https://stock-news.laohu8.com/highlight/detail?id=1150632681","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150632681?lang=zh_cn&edition=full","pubTime":"2026-06-15 14:22","pubTimestamp":1781504520,"startTime":"0","endTime":"0","summary":"6月15日，康方生物盘中下跌3.04%，报89.2港元，成交额13.48亿港元。此前公司董事会批准最多2亿港元回购计划曾短暂提振股价，但ASCO利好兑现后的持续抛压再度主导走势。消息面上，公司核心产品依沃西HARMONi-6研究OS阳性结果于6月1日ASCO全体会议公布后，事件驱动型资金持续获利了结，叠加美方可能限制对中国生物技术投资的传闻扰动及市场对创新药盈利能力的担忧，板块整体承压。尽管多家券商维持买入评级，资金面抛压仍主导短线走势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880383366.USD","09996","BK1576","SG9999002562.SGD","01093","HK0000320264.USD","06990","BK1191","LU1960683339.HKD","01530","LU0819121731.USD","LU2097828631.EUR","IE00BZ08YR35.GBP","LU0737861772.HKD","LU0348827113.USD","03329","IE00B0JY6N72.USD","01801","LU0456827905.SGD","02596","01276","LU0320764599.SGD","01177","HK0000306685.HKD","06160","02269","09926","03692","LU2399975544.HKD","02273","06821","LU0181495838.USD","00013","06078","06996","LU0140636845.USD","LU1242518857.USD","LU3063872942.SGD","02268","01951","02096","03759","09966","LU1226287875.USD","01952","LU1688375341.USD","LU0502904849.HKD","02162","LU0051755006.USD","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642254781","title":"医药板块集体回升 科伦博泰生物(06990)涨7.20%、荣昌生物(09995)涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642254781","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642254781?lang=zh_cn&edition=full","pubTime":"2026-06-12 13:30","pubTimestamp":1781242214,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药板块集体回升，科伦博泰生物 涨7.20%，荣昌生物涨6.53%，康诺亚-B涨5.58%，复宏汉霖涨5.36%，康方生物涨5.07%，君实生物涨4.61%，药明合联涨4.06%，诺诚健华涨3.96%。英伟达同时为 Abridge 投资方，新模型基于英伟达开放模型套件 Nemotron 训练，Abridge 将采用去标识化临床数据进行定制优化，预计 2026 年晚些时候上线。东莞证券研报认为，受行业合规整顿以及消费疲软等因素影响，2025年医药生物行业整体归母净利润同比有所下滑。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983673","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","06990","BK1515","HK0000165453.HKD","BK1161","BK1583","LU0417516738.SGD","BK1587","HK0000306685.HKD","LU2488822045.USD","BK1141","LU0540923850.HKD","IE00BPRC5H50.USD","LU1064131003.USD","02268","LU0417516571.SGD","LU2399975544.HKD","159938","LU0348766576.USD","LU2328871848.SGD","688331","SG9999014674.SGD","LU2148510915.USD","BK1574","HK0000320264.USD","09939","01877","LU1961090484.USD","LU2476274720.SGD","09995","09969","LU0417516902.SGD","LU0634319403.HKD","LU1064130708.USD","02162","LU1720050803.USD","LU0561508036.HKD","HK0000306701.USD","HK0000320223.HKD","09926","LU1969619763.USD","LU0348735423.USD","LU1794554557.SGD","LU0348825331.USD","LU0348783233.USD","02696","LU0348784397.USD","LU2476274308.USD","BK0239","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642640584","title":"康方生物(09926)拟斥资最多2亿港元回购股份 执行董事及高级管理层拟增加持股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642640584","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642640584?lang=zh_cn&edition=full","pubTime":"2026-06-11 12:06","pubTimestamp":1781150805,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，于2026年6月11日，本公司董事会批准动用最多2亿港元以在公开市场上购买本公司普通股(股份)。建议购买股份将由本公司 2021年受限制股份单位计划的受托人执行。建议购买股份显示董事会及管理层对本公司业务展望及前景充满信心，并将从而惠及本公司，为股东创造价值。建议购买股份将由本公司现有可用现金资源拨付。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348827113.USD","LU0348767384.USD","IE00BPRC5H50.USD","LU1961090484.USD","LU1720050803.USD","IE00B543WZ88.USD","LU0348766576.USD","LU0634319403.HKD","LU2488822045.USD","LU2476274720.SGD","LU0348783233.USD","BK1574","09926","LU0348735423.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2399975544.HKD","LU0540923850.HKD","LU0417516738.SGD","LU0417516571.SGD","LU0348784397.USD","LU0417516902.SGD","LU0561508036.HKD","LU2778985437.USD","BK1161","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186500981","title":"异动解读｜康方生物盘中下跌3.24%，ASCO利好兑现后延续回调逼近52周低位","url":"https://stock-news.laohu8.com/highlight/detail?id=1186500981","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186500981?lang=zh_cn&edition=full","pubTime":"2026-06-11 09:37","pubTimestamp":1781141828,"startTime":"0","endTime":"0","summary":"6月11日，康方生物盘中下跌3.24%，报86.05港元，成交额8274.67万港元，股价逼近52周低点82.15港元，较6月1日ASCO数据公布后高点累计跌幅已逾30%。消息面上，该股延续ASCO利好兑现后的持续回调走势。尽管中泰证券、国泰海通等多家机构近日维持买入评级，但资金面抛压仍主导股价走势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642207443","title":"【券商聚焦】中泰证券首予康方生物(09926)“买入”评级 指核心双抗管线有望重新定义治疗标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642207443","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642207443?lang=zh_cn&edition=full","pubTime":"2026-06-10 15:08","pubTimestamp":1781075315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰证券发布研报指，康方生物 核心双抗管线AK112（依沃西）的15项III期临床齐头并进，覆盖NSCLC、结直肠癌等大适应症，近期HARMONi-6研究入选2026ASCO全体大会，验证AK112联合化疗在1L肺鳞癌中相对标准疗法替雷利珠单抗的PFS及OS双获益，有望重新定义一线治疗标准。商业化层面，公司5个自研新药所有适应症均纳入2025年国家医保，包括AK112、AK104新增一线大适应症，将加速市场渗透。首次覆盖，给予“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983467","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","600918"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125573325","title":"异动解读｜康方生物盘中下跌3.35%，ASCO利好兑现后延续回调跌至52周低位附近","url":"https://stock-news.laohu8.com/highlight/detail?id=1125573325","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125573325?lang=zh_cn&edition=full","pubTime":"2026-06-10 10:04","pubTimestamp":1781057085,"startTime":"0","endTime":"0","summary":"6月10日，康方生物盘中下跌3.35%，报85.85港元，成交额3.65亿港元，股价已逼近52周低点82.15港元，较6月1日ASCO数据公布后高点累计跌幅逾25%。消息面上，该股延续ASCO利好兑现后的持续回调走势。此前公司核心产品依沃西联合化疗HARMONi-6研究在ASCO全体会议公布OS阳性结果，事件驱动型资金在利好落地后持续获利了结。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129687513","title":"异动解读｜康方生物盘中下跌3.36%，ASCO利好兑现后延续回调生物科技板块集体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1129687513","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129687513?lang=zh_cn&edition=full","pubTime":"2026-06-09 09:44","pubTimestamp":1780969478,"startTime":"0","endTime":"0","summary":"6月9日，康方生物盘中下跌3.36%，报88.65港元，成交额2.04亿港元，股价延续此前连续回调走势。消息面上，该股自6月1日核心产品依沃西联合化疗HARMONi-6研究在ASCO全体会议公布OS阳性结果后持续走弱，上周累计跌幅超20%，市值蒸发超百亿港元。市场分析认为，ASCO核心数据披露完毕后事件驱动型资金获利了结，叠加外媒关于美方可能限制对中国生物技术领域投资的传闻扰动，短线情绪持续承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641177986","title":"东方证券：国产创新药开启NSCLC一线治疗范式革新","url":"https://stock-news.laohu8.com/highlight/detail?id=2641177986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641177986?lang=zh_cn&edition=full","pubTime":"2026-06-08 09:55","pubTimestamp":1780883706,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：一代PD-1单药±化疗标准松动，NSCLC一线进入二代IO、ADC+IO双线迭代周期本届ASCO大会上，来自国产创新药的三项重磅临床数据表明，NSCLC一线金标准，即传统的PD-1±化疗的正迎来系统性替代。在免疫1.0时代，国产创新药大多跟随海外PD-1药物的研发，如今快速发展至引领免疫2.0时代，有望创造肺癌千亿市场治疗范式的全面革新。该研究是全球首个ADC+IO一线NSCLC取得III期阳性结果，有望改写PD-L1阳性NSCLC一线用药格局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","06990","09926","01801","LU2097828631.EUR","06978","LU0348735423.USD","LU0348825331.USD","LU0348783233.USD","LU2097828474.EUR","LU0348766576.USD","IE00B543WZ88.USD","LU1969619763.USD","LU1720050803.USD","LU0348784397.USD","LU0455707207.USD","LU0348827113.USD","LU0502904849.HKD","HK0000165453.HKD","BK1564","LU0417516571.SGD","BK0028","LU0417516738.SGD","BK0183","LU2488822045.USD","03958","BK0276","LU0348767384.USD","LU2097828557.USD","159992","BK1147","LU0634319403.HKD","LU0540923850.HKD","LU2328871848.SGD","BK1574","BK1589","LU1794554557.SGD","BK1161","LU2476274308.USD","LU0417516902.SGD","LU2778985437.USD","600958","LU2476274720.SGD","LU0561508036.HKD","LU2097828714.EUR","BK0012","LU1961090484.USD","IE00B5MMRT66.SGD","LU0196878994.USD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148362","title":"康方新药取得历史性突破，为何蒸发百亿市值","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148362","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641148362?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:42","pubTimestamp":1780659720,"startTime":"0","endTime":"0","summary":"6月1日，康方生物开盘后一度涨超12%，然而高开低走，此后三日连续下跌，截至6月5日收盘，康方生物总市值862亿港元，数日内市值跌去超百亿。在康方生物的叙述中，这份登陆ASCO全体会议的临床数据堪称历史性突破。无可辩驳的是，康方生物的HARMONi-6已达到全部预期终点，取得显著阳性。股价为何下跌数据公布后3日，康方生物的市值跌去超百亿港元，截至发稿，总市值已不足千亿。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0417516571.SGD","02616","LU2399975544.HKD","BK1574","LU0348735423.USD","06978","LU0417516738.SGD","LU0348827113.USD","BK4225","BK4195","LU0348825331.USD","LU0417516902.SGD","LU0348784397.USD","BK1161","PFS","BK4211","LU1794554557.SGD","LU2476274308.USD","BK4203","LU2488822045.USD","LU0348767384.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU1720050803.USD","HR","LU0348783233.USD","LU1961090484.USD","LU2476274720.SGD","IE00BPRC5H50.USD","LU0634319403.HKD","LU0561508036.HKD","LU0348766576.USD","IE00B5MMRT66.SGD","LU2778985437.USD","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169555198","title":"异动解读 | 康方生物盘中大跌5.23%，疑因出现大手卖出交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1169555198","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169555198?lang=zh_cn&edition=full","pubTime":"2026-06-05 15:26","pubTimestamp":1780644409,"startTime":"0","endTime":"0","summary":"康方生物（09926）今日盘中股价出现大幅下跌，跌幅达5.23%，引发市场关注。消息面上，该股票在交易时段内出现一笔大手卖出交易，涉及7.6万股，成交价为95.0港元，涉资约722万港元。此类大额抛售行为通常会对股价造成直接的下行压力，可能是导致本次盘中急跌的主要原因。尽管同一时段有券商发布研报，维持对康方生物“优于大市”的评级，并看好其核心产品依沃西的临床进展与商业化前景，但市场短期交易行为，尤其是大额卖单的出现，似乎主导了股价的走势。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105055909","title":"异动解读｜康方生物盘中上涨3.07%，连续回调后技术性反弹叠加多家机构维持买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1105055909","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105055909?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:31","pubTimestamp":1780623088,"startTime":"0","endTime":"0","summary":"6月5日，康方生物盘中上涨3.07%，报102.6港元，成交额1883.22万港元。该股此前因ASCO大会利好兑现后连续四个交易日下跌，累计跌幅超14%，股价一度跌破100港元整数关口，今日出现技术性反弹。消息面上，近日多家机构密集发布研报维持看好评级：中金给予目标价184港元并维持跑赢行业评级，交银国际维持买入评级目标价175港元，野村将评级上调至买入，中信建投维持买入评级，国信证券维持优于大市评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155332","title":"中金：2026 ASCO大会正式闭幕 国产新药闪耀国际学术会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155332","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155332?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:52","pubTimestamp":1780563131,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，本次ASCO大会中国研究数量和质量实现双提升，国产创新药逐渐成为全球FIC/BIC研发核心力量。中金主要观点如下：当地时间6月2日，2026 ASCO大会于美国芝加哥正式闭幕本次大会共94 项中国研究入选口头汇报，其中康方生物HARMONi-6 入选Plenary Session;LBA共13 项，OralAbstract Session、Rapid Abstract Session 等专场入选数量均创历年新高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348827113.USD","LU0417516738.SGD","BK1161","LU2488822045.USD","LU0348767384.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0417516571.SGD","LU2778985437.USD","LU2399975544.HKD","IE00B543WZ88.USD","LU0348766576.USD","BK1574","LU1961090484.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0417516902.SGD","LU0634319403.HKD","LU1720050803.USD","09926","LU0348735423.USD","LU1794554557.SGD","LU0348825331.USD","LU0348783233.USD","LU0348784397.USD","LU2476274308.USD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178555978","title":"康方生物5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178555978","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178555978?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:43","pubTimestamp":1780562610,"startTime":"0","endTime":"0","summary":"康方生物科技（开曼）有限公司于2026年6月4日公布了截至2026年5月31日的证券变动月报表。公告显示，公司在本报告期内整体股本状况保持稳定，未发生新的股份发行或回购活动。已发行股本截至5月底为921,143,176股，与上月底持平，且库存股份数仍为0。本月末因购股权行使可能发行股份数为1,059,500股，若全部已授予的购股权行使，可发行或转让股份合计76,217,717股。本公告由董事夏瑜签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640158294","title":"国信证券：维持康方生物(09926)“优于大市”评级 依沃西取得历史性突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2640158294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640158294?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:01","pubTimestamp":1780560101,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，康方生物的核心产品依沃西在HARMONi-6临床中获得统计学显著且具有临床意义的OS获益，进一步奠定了依沃西在下一代IO治疗中的基石地位。康方生物具备全球化的研发能力，产品的大适应症在国内纳入医保预计将快速放量，维持“优于大市”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002736","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640132568","title":"【券商聚焦】中信建投证券维持康方生物(09926)“买入”评级 指其肺癌研究重新定义治疗金标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640132568","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640132568?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:14","pubTimestamp":1780553653,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，康方生物 于2026 ASCO上发表HARMONi-6研究中期OS分析，结果显著阳性，HR=0.66,成为全球首个在肺癌领域对比PD-1联合化疗取得OS和PFS双显著阳性结果的III期研究，重新定义了sq-NSCLC一线治疗的金标准。报告预计公司2026、2027、2028年营业收入分别为48.22、76.14、106.11亿元，对应增速为57.77%、57.90%、39.36%；归母净利润分别为0.2、10.91、21.44亿元。考虑到公司创新药产品疗效优秀、市场空间广阔，给予“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132463678","title":"异动解读 | 康方生物盘中大跌5.26%，ASCO利好兑现后回调叠加传闻扰动","url":"https://stock-news.laohu8.com/highlight/detail?id=1132463678","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132463678?lang=zh_cn&edition=full","pubTime":"2026-06-04 10:43","pubTimestamp":1780540992,"startTime":"0","endTime":"0","summary":"康方生物今日盘中股价大跌5.26%，引起市场关注。消息面上，该股延续了在美国临床肿瘤学会（ASCO）年会利好兑现后的持续回调趋势。此前，公司核心产品依沃西联合化疗的HARMONi-6研究在ASCO全体会议上公布了总生存期（OS）阳性结果，但股价在数据公布后冲高回落。市场分析认为，ASCO核心数据披露完毕后，事件驱动型资金选择获利了结。此外，外媒关于美方可能限制对中国生物技术领域投资的相关传闻也对市场短线情绪造成扰动，导致股价承压。尽管股价短线调整，但多家机构仍对公司前景维持看好，并给予了较高的目标价。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124446193","title":"异动解读｜康方生物盘中下跌3.16%，ASCO利好兑现后延续回调股价跌破百元关口","url":"https://stock-news.laohu8.com/highlight/detail?id=1124446193","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124446193?lang=zh_cn&edition=full","pubTime":"2026-06-04 10:22","pubTimestamp":1780539726,"startTime":"0","endTime":"0","summary":"6月4日，康方生物盘中下跌3.16%，报99.45港元，成交额4.18亿港元，股价跌破100港元整数关口。消息面上，该股延续ASCO利好兑现后的持续回调。此前6月1日，公司核心产品依沃西联合化疗HARMONi-6研究在ASCO全体会议公布OS阳性结果，当日股价冲高回落，此后连续三日下跌，累计跌幅超14%。市场分析认为，ASCO核心数据披露完毕后事件驱动型资金获利了结，叠加外媒关于美方可能限制对中国生物技术投资等传闻扰动，短线情绪持续承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0537},{"period":"1month","weight":-0.2958},{"period":"3month","weight":-0.2952},{"period":"6month","weight":-0.2696},{"period":"1year","weight":-0.1437},{"period":"ytd","weight":-0.2509}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":-0.0566},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.0394},{"period":"1year","weight":0.018},{"period":"ytd","weight":-0.0443}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.073739},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}